Device Trial Radar · NCT02139072
CoaguChek XS in Antiphospholipid Antibody Syndrome (APL) Patients
Last checked: Nov 19, 2026Latest source record: Oct 4, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
60
Actual
Start
Mar 2015
Primary completion
Jan 2016
Study completion Jan 2016
Sponsor
- Lead sponsor
- University of FloridaAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Hoffmann-La Roche
- First posted
- May 15, 2014
Design
- Study type
- Observational
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to see if the CoaguChek XS is accurate in measuring International Normalized Ratio (INR) in patients with Antiphospholipid Antibody Syndrome (APL) receiving warfarin therapy.
Conditions
- Antiphospholipid Antibody Syndrome
Interventions
CoaguChek XSDevice
CoaguChek XS will be used to measure INR in patients with APL
Standard Lab DrawProcedure
Patients on warfarin for any indication other than APL will measure INR by venous lab draw
Primary outcomes
What the sponsor says the trial is designed to measure.
- International Normalized Ratio (INR)Time frame: Day 1 and Day 60
Locations
1 site in 1 country. Site status is shown where the registry gives one.
UF and Shands Health
Gainesville, Florida
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.